Group | No. of trials | Cisplatin | Non-cisplatin | I2(%) | OR (95%CI) | P | |||
---|---|---|---|---|---|---|---|---|---|
No. of events | No. of patients | No. of events | No. of patients | OR | Interaction | ||||
Type of control | 0.93 | ||||||||
 Non-platinum | 20 | 48 | 2856 | 40 | 2395 | 29 | 0.94 [0.60, 1.45] | 0.77 |  |
 Other platinum | 8 | 27 | 1077 | 28 | 1075 | 0 | 0.97 [0.56, 1.66] | 0.90 |  |
Total cisplatin dose(mg/m2) | 0.85 | ||||||||
 ≤ 300 | 16 | 50 | 2461 | 41 | 1946 | 0 | 0.94 [0.61, 1.46] | 0.80 |  |
 > 300 | 11 | 22 | 1323 | 26 | 1389 | 43 | 0.88 [0.50, 1.56] | 0.66 |  |
Follow-up time(months) | 0.77 | ||||||||
 ≤ 60 | 18 | 40 | 2221 | 39 | 2203 | 4 | 0.99 [0.63, 1.56] | 0.97 |  |
 > 60 | 10 | 35 | 1712 | 29 | 1267 | 30 | 0.89 [0.53, 1.50] | 0.67 |  |
Mode of treatment | 0.78 | ||||||||
 Chemotherapy alone | 19 | 30 | 2187 | 34 | 2247 | 19 | 0.90 [0.55, 1.48] | 0.68 |  |
 Chemotherapy and radiotherapy | 9 | 45 | 1746 | 34 | 1223 | 5 | 0.99 [0.62, 1.59] | 0.98 |  |
Mode of comparison | 0.40 | ||||||||
 Un-confounded | 16 | 53 | 2602 | 51 | 2228 | 28 | 0.88 [0.59, 1.32] | 0.54 |  |
 Confounded | 13 | 22 | 1331 | 18 | 1318 | 0 | 1.21 [0.65, 2.28] | 0.54 |  |
Treatment setting | 0.50 | ||||||||
 Adjuvant | 20 | 61 | 2747 | 56 | 2252 | 0 | 0.90 [0.62, 1.31] | 0.65 |  |
 Metastasis | 8 | 14 | 1186 | 12 | 1218 | 0 | 1.18 [0.59, 2.37] | 0.58 |  |